Screener / SEC EDGAR /CIK 0000887359 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Vericel Corp VCEL

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What VCEL's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year

Open on SEC

Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T617 588-5555F617 588-5554 www.vcel.com

Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28%

Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., November 5, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2026.

• Burn Care net revenue growth of 52% to $18.0 million, with Epicel ® revenue of $12.7 million and NexoBrid ® revenue of $5.3 million

• Record third quarter total revenue and MACI revenue, and the highest quarterly Burn Care revenue to date

• Highest Epicel quarterly revenue since launch, which increased 23% versus the prior year

• Highest NexoBrid quarterly commercial revenue since launch, with 54% growth versus the prior year and 46% growth versus the prior quarter

• Record third quarter MACI biopsies, implants and biopsy and implanting surgeons, with biopsy growth increasing each quarter this year compared to the prior year

• Highest number of MACI Arthro cases in any quarter since launch in the third quarter

• Repurchased 220,744 shares of common stock for $8.8 million during the quarter, with $191.2 million of share repurchase authorization remaining as of September 30, 2026

“The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders,” said Nick Colangelo, President and CEO of Vericel. “Given our third quarter outperformance and the strong start to the fourth quarter for both commercial businesses, and particularly for MACI, we believe that the Company is very well- positioned for a strong close to 2026 and to sustain this momentum in 2027 and beyond.”

• Raised total revenue guidance to $344 to $346 million, compared to $330 to $340 million previously

• Raised MACI revenue guidance to $290 to $292 million, compared to $284 to $290 million previously

• Raised Burn Care revenue guidance to $54 million, compared to $46 to $50 million previously

Total net revenue for the quarter ended September 30, 2026 increased 26% to $85.4 million, compared to $67.5 million in the third quarter of 2025. Total net product revenue for the quarter included $67.4 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue, $12.7 million of Epicel (cultured epidermal autografts) net revenue, $2.3 million of NexoBrid (anacaulase-bcdb) commercial net revenue and $3.0 million of NexoBrid BARDA procurement revenue, compared to $55.7 million of MACI net revenue, $10.4 million of Epicel net revenue, and $1.5 million of commercial NexoBrid net revenue, respectively, in the third quarter of 2025. 2

Gross profit for the quarter ended September 30, 2026 was $62.6 million, or 73% of net revenue, compared to $49.6 million, or 73% of net revenue, for the third quarter of 2025.

Total operating expenses for the quarter ended September 30, 2026 were $50.4 million, compared to $46.1 million for the same period in 2025. The increase in operating expenses was primarily due to increased headcount and related employee expenses, including the MACI sales force expansion, and an increase in marketing programs.

Net income for the quarter ended September 30, 2026 was $14.2 million, or $0.27 per diluted share, compared to $5.1 million, or $0.10 per diluted share, for the third quarter of 2025.

Non-GAAP adjusted EBITDA for the quarter ended September 30, 2026 was $25.2 million, or 30% of net revenue, compared to $17.0 million, or 25% of net revenue, for the third quarter of 2025. A table reconciling non-GAAP measures is included in this press release for reference.

Today’s conference call will be available live at 8:30 a.m. Eastern Time. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the Vericel website. A replay of the webcast will be available until November 5, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connecting, please use passcode: 787594.

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.

Epicel ® , MACI ® and MACI Arthro ® are registered trademarks of Vericel Corporation. NexoBrid ® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved. 3

Vericel’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission (SEC). Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA, which includes adjustments for specific items that are generally not indicative of our core operations, and free cash flow described in this release, provide additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.

Vericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI, MACI Arthro, Epicel, and NexoBrid in the U.S. and in applicable markets outside the U.S., growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, the ability to sustain profitability, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the use of MACI to treat cartilage defects in the ankle, the timing and likelihood of obtaining marketing approval for MACI in the United Kingdom, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, including recent and future healthcare and drug pricing reform measures and private payor initiatives, surgeon adoption of MACI Arthro, physician and burn center 4

adoption of NexoBrid, labor strikes, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to conflicts in the Middle East region involving Israel or those related to disruptions of land or sea transportation routes or distribution or shipping channels, uncertainties associated with the potential benefits of the Company’s agreement with BARDA for the procurement and development of NexoBrid and the availability of funding from BARDA under that agreement, negative impacts on the global economy and capital markets resulting from the conflicts in Ukraine and Iran, as well as other hostilities in the Middle East, changes in trade policies and regulations, including the potential for increases or changes in duties, current and potentially new tariffs or quotas, lingering effects of adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures, the impact from future regulatory, judicial and legislative changes affecting our industry or the broader market, including those included in the One Big Beautiful Bill Act, and a U.S. government shutdown.

These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, Vericel’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 5, 2026, and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 133,493 $ 100,092 Short-term investments 36,775 37,407 Accounts receivable (net of allowance for doubtful accounts of 81,798 84,634 $23 and $13, respectively) Inventory 17,056 17,560 Other current assets 11,648 7,744 Total current assets 280,770 247,437 Property and equipment, 105,079 108,397 net Intangible assets, net 5,156 5,625 Right-of-use assets 60,590 64,774 Long-term investments 65,336 61,395 Other long-term assets 179 341 Total assets $ 517,110 $ 487,969 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable $ 19,958 $ 15,828 Accrued expenses 20,391 19,236 Current portion of operating lease 14,254 13,969 liabilities Other current liabilities 116 116 Total current liabilities 54,719 49,149 Operating lease 76,319 82,284 liabilities Other long-term 1,900 1,896 liabilities Total liabilities 132,938 133,329 Total shareholders’ 384,172 354,640 equity Total liabilities and shareholders’ $ 517,110 $ 487,969 equity

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
  Vericel Corporation                                                           
  25 Blue Sky Drive                                                             
  Burlington, MA 01803                                                          
  T617 588-5555F617 588-5554                                                    
  www.vcel.com                                                                  
                                                                                
   Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year    
                               Financial Guidance                               
                                                                                
                  Total Revenue Growth of 26% to $85.4 Million                  
                                                                                
                                                                                
                   Net Income Increased 179% to $14.2 Million                   
                                                                                
                                                                                
                         Adjusted EBITDA Margin of 30%                          
                                                                                
 Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA  
                             Margin Guidance to 28%                             
                                                                                
                  Conference Call Today at 8:30am Eastern Time                  
BURLINGTON, Mass., November 5, 2026 (GLOBE NEWSWIRE) — Vericel Corporation
(NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe
burn care markets, today reported financial results and business highlights for
the third quarter ended September 30, 2026.
                                                                                
   Third Quarter 2026 Financial Highlights                                      
                                                                                
• Total net revenue growth of 26% to $85.4 million

• MACI ® net revenue growth of 21% to $67.4 million

• Burn Care net revenue growth of 52% to $18.0 million, with Epicel ® revenue of
$12.7 million and NexoBrid ® revenue of $5.3 million

• Gross margin of 73%

• Net income increased 179% to $14.2 million, or $0.27 per diluted share

• Non-GAAP adjusted EBITDA increased 48% to $25.2 million, or 30% of revenue

• Operating cash flow of $17.7 million

• Free cash flow of $15.7 million

• $235.6 million in cash and investments, and no debt
                                                                                
   Year-to-Date 2026 Financial Highlights                                       
                                                                                
• Total net revenue growth of 26% to $231.3 million

• MACI net revenue growth of 22% to $189.3 million

• Burn Care net revenue growth of 50% to $42.0 million

• Adjusted EBITDA growth of 48% to $49.6 million

• Operating cash flow of $50.3 million

• Free cash flow of $45.1 million
                                       1                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
  Business Highlights and Updates                                               
                                                                                
• Record third quarter total revenue and MACI revenue, and the highest quarterly
Burn Care revenue to date

• MACI revenue growth of 20% or more for the sixth consecutive quarter

• Highest Epicel quarterly revenue since launch, which increased 23% versus the
prior year

• Highest NexoBrid quarterly commercial revenue since launch, with 54% growth
versus the prior year and 46% growth versus the prior quarter

• Recognized $3.0 million of BARDA procurement revenue in the third quarter

• Record third quarter MACI biopsies, implants and biopsy and implanting
surgeons, with biopsy growth increasing each quarter this year compared to the
prior year

• Highest number of MACI Arthro cases in any quarter since launch in the third
quarter

• The Company remains on track for a potential MACI launch in the U.K. in 2027

• Repurchased 220,744 shares of common stock for $8.8 million during the
quarter, with $191.2 million of share repurchase authorization remaining as of
September 30, 2026

“The Company delivered outstanding financial and business results in the third
quarter as we continue to generate top-tier revenue and profit growth as well as
significant free cash flow, while also returning capital to shareholders,” said
Nick Colangelo, President and CEO of Vericel. “Given our third quarter
outperformance and the strong start to the fourth quarter for both commercial
businesses, and particularly for MACI, we believe that the Company is very well-
positioned for a strong close to 2026 and to sustain this momentum in 2027 and
beyond.”
                                                                                
   2026 Full-Year Financial Guidance                                            
                                                                                
• Raised total revenue guidance to $344 to $346 million, compared to $330 to
$340 million previously

• Raised MACI revenue guidance to $290 to $292 million, compared to $284 to $290
million previously

• Raised Burn Care revenue guidance to $54 million, compared to $46 to $50
million previously

• Raised adjusted EBITDA margin guidance to 28%, compared to 27% previously

• Reaffirmed full-year gross margin of approximately 75%
                                                                                
   Third Quarter 2026 Results                                                   
                                                                                
Total net revenue for the quarter ended September 30, 2026 increased 26% to
$85.4 million, compared to $67.5 million in the third quarter of 2025. Total net
product revenue for the quarter included $67.4 million of MACI (autologous
cultured chondrocytes on porcine collagen membrane) net revenue, $12.7 million
of Epicel (cultured epidermal autografts) net revenue, $2.3 million of NexoBrid
(anacaulase-bcdb) commercial net revenue and $3.0 million of NexoBrid BARDA
procurement revenue, compared to $55.7 million of MACI net revenue, $10.4
million of Epicel net revenue, and $1.5 million of commercial NexoBrid net
revenue, respectively, in the third quarter of 2025.
                                       2                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
Gross profit for the quarter ended September 30, 2026 was $62.6 million, or 73%
of net revenue, compared to $49.6 million, or 73% of net revenue, for the third
quarter of 2025.

Total operating expenses for the quarter ended September 30, 2026 were $50.4
million, compared to $46.1 million for the same period in 2025. The increase in
operating expenses was primarily due to increased headcount and related employee
expenses, including the MACI sales force expansion, and an increase in marketing
programs.

Net income for the quarter ended September 30, 2026 was $14.2 million, or $0.27
per diluted share, compared to $5.1 million, or $0.10 per diluted share, for the
third quarter of 2025.

Non-GAAP adjusted EBITDA for the quarter ended September 30, 2026 was $25.2
million, or 30% of net revenue, compared to $17.0 million, or 25% of net
revenue, for the third quarter of 2025. A table reconciling non-GAAP measures is
included in this press release for reference.
                                                                                
  Conference Call Information                                                   
                                                                                
Today’s conference call will be available live at 8:30 a.m. Eastern Time. The
live webcast can be accessed on the Investor Relations section of the Vericel
website at http://investors.vcel.com/events-presentations. Presentation slides
for the conference call will be available on the webcast and on the Vericel
website. A replay of the webcast will be available until November 5, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting
from outside the U.S. When connecting, please use passcode: 787594.
                                                                                
  About Vericel Corporation                                                     
                                                                                
Vericel is a leading provider of advanced therapies for the sports medicine and
severe burn care markets. The Company combines innovations in biology with
medical technologies, resulting in a highly differentiated portfolio of
innovative cell therapies and specialty biologics that repair injuries and
restore lives. Vericel markets three products in the United States. MACI
(autologous cultured chondrocytes on porcine collagen membrane) is an autologous
cellularized scaffold product indicated for the repair of symptomatic, single or
multiple full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel (cultured epidermal autografts) is a permanent
skin replacement for the treatment of patients with deep dermal or full
thickness burns greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to NexoBrid
(anacaulase-bcdb), a biological orphan product containing proteolytic enzymes,
which is indicated for eschar removal in adults and pediatric patients with deep
partial-thickness and/or full-thickness thermal burns. For more information,
please visit www.vcel.com.

Epicel ® , MACI ® and MACI Arthro ® are registered trademarks of Vericel
Corporation. NexoBrid ® is a registered trademark of MediWound Ltd. and is used
under license to Vericel Corporation. © 2026 Vericel Corporation. All rights
reserved.
                                       3                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
  GAAP v. Non-GAAP Measures                                                     
                                                                                
Vericel’s reported earnings are prepared in accordance with generally accepted
accounting principles in the United States, or GAAP, and represent earnings as
reported to the Securities and Exchange Commission (SEC). Vericel has provided
in this release certain financial information that has not been prepared in
accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted
EBITDA, which includes adjustments for specific items that are generally not
indicative of our core operations, and free cash flow described in this release,
provide additional information that is useful to investors in understanding
Vericel’s underlying performance, business and performance trends, and helps
facilitate period-to-period comparisons and comparisons of its financial
measures with other companies in Vericel’s industry. However, the non-GAAP
financial measures that Vericel uses may differ from measures that other
companies may use. Non-GAAP financial measures are not required to be uniformly
applied, are not audited and should not be considered in isolation or as
substitutes for results prepared in accordance with GAAP.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
Vericel cautions you that all statements other than statements of historical
fact included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may occur in the
future are forward-looking statements. Although we believe that we have a
reasonable basis for the forward-looking statements contained herein, they are
based on current expectations about future events affecting us and are subject
to risks, assumptions, uncertainties and factors relating to our operations and
business environment, all of which are difficult to predict and many of which
are beyond our control. Our actual results may differ materially from those
expressed or implied by the forward-looking statements in this press release.
These statements are often, but are not always, made through the use of words or
phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,”
“continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,”
“goals” and similar words or phrases, or future or conditional verbs such as
“will,” “would,” “should,” “could,” “may,” or similar expressions.

Among the factors that could cause actual results to differ materially from
those set forth in the forward-looking statements include, but are not limited
to, uncertainties associated with our expectations regarding future revenue,
growth in revenue, market penetration for MACI, MACI Arthro, Epicel, and
NexoBrid in the U.S. and in applicable markets outside the U.S., growth in
profit, gross margins and operating margins, the ability to continue to scale
our manufacturing operations to meet the demand for our cell therapy products,
the ability to sustain profitability, the expected target surgeon audience,
potential fluctuations in sales and volumes and our results of operations over
the course of the year, timing and conduct of clinical trial and product
development activities, timing and likelihood of the FDA’s potential approval of
the use of MACI to treat cartilage defects in the ankle, the timing and
likelihood of obtaining marketing approval for MACI in the United Kingdom, the
estimate of the commercial growth potential of our products and product
candidates, competitive developments, changes in third-party coverage and
reimbursement, including recent and future healthcare and drug pricing reform
measures and private payor initiatives, surgeon adoption of MACI Arthro,
physician and burn center
                                       4                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
adoption of NexoBrid, labor strikes, supply chain disruptions or other events or
factors that might affect our ability to manufacture MACI or Epicel or affect
MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid
to meet customer demand, including but not limited to conflicts in the Middle
East region involving Israel or those related to disruptions of land or sea
transportation routes or distribution or shipping channels, uncertainties
associated with the potential benefits of the Company’s agreement with BARDA for
the procurement and development of NexoBrid and the availability of funding from
BARDA under that agreement, negative impacts on the global economy and capital
markets resulting from the conflicts in Ukraine and Iran, as well as other
hostilities in the Middle East, changes in trade policies and regulations,
including the potential for increases or changes in duties, current and
potentially new tariffs or quotas, lingering effects of adverse developments
affecting financial institutions, companies in the financial services industry
or the financial services industry generally, changes in governmental monetary
and fiscal policies, including, but not limited to, Federal Reserve policies in
connection with continued inflationary pressures, the impact from future
regulatory, judicial and legislative changes affecting our industry or the
broader market, including those included in the One Big Beautiful Bill Act, and
a U.S. government shutdown.

These and other significant factors are discussed in greater detail in Vericel’s
Annual Report on Form 10-K for the year ended December 31, 2025, filed with the
SEC on February 26, 2026, Vericel’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2026, filed with the SEC on November 5, 2026, and in
other filings with the SEC. These forward-looking statements reflect our views
as of the date hereof and Vericel does not assume and specifically disclaims any
obligation to update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date of this
release except as required by law.

Investor Contact:

Eric Burns

[email protected]

+1 (734) 418-4411
                                       5                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                              VERICEL CORPORATION                               
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                 
                                                                                
              (in thousands, except per share amounts - unaudited)              
                                                                                
                      Three                              Nine                   
                     Months                            Months                   
                      Ended                             Ended                   
                   Septemb…                          Septemb…                   
             2026       30,    2025            2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Product                                                                       
  sales,     $       85,371    $     67,503    $      231,253    $     183,341  
  net                                                                           
  Total              85,371          67,503           231,253          183,341  
  revenue                                                                       
  Cost of                                                                       
  product            22,761          17,918            62,975           50,870  
  sales                                                                         
  Gross              62,610          49,585           168,278          132,471  
  profit                                                                        
  Resear…                                                                       
  and                 6,885           6,318            22,482           20,310  
  develo…                                                                       
  Sellin…                                                                       
  general            43,539          39,817           141,240          123,532  
  and                                                                           
  admini…                                                                       
  Total                                                                         
  operat…            50,424          46,135           163,722          143,842  
  expens…                                                                       
  Income                                                                        
  (loss)             12,186           3,450             4,556          -11,371  
  from                                                                          
  operat…                                                                       
  Other                                                                         
  income                                                                        
  (expen…                                                                       
  Intere…             2,152           1,808             5,957            5,122  
  income                                                                        
  Intere…              -160            -158              -480             -468  
  expense                                                                       
  Other                                                                         
  (expen…               -17             -26                32               -8  
  income                                                                        
  Total                                                                         
  other               1,975           1,624             5,509            4,646  
  income                                                                        
  Net                                                                           
  income     $       14,161    $      5,074    $       10,065    $      -6,725  
  (loss)                                                                        
  Net                                                                           
  income                                                                        
  (loss)                                                                        
  per                                                                           
  common                                                                        
  share:                                                                        
  Basic      $         0.28    $       0.10    $         0.20    $       -0.13  
  Diluted    $         0.27    $       0.10    $         0.19    $       -0.13  
  Weight…                                                                       
  common                                                                        
  shares                                                                        
  outsta…                                                                       
  Basic              51,186          50,489            51,013           50,256  
  Diluted            52,962          51,908            52,459           50,256  
                                                                                
                                       6                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                              VERICEL CORPORATION                               
                                                                                
              RECONCILIATION OF REPORTED NET INCOME (LOSS) (GAAP)               
                                                                                
                     TO ADJUSTED EBITDA (NON-GAAP MEASURE)                      
                                                                                
                           (in thousands - unaudited)                           
                                                                                
                       Three                              Nine                  
                      Months                            Months                  
                       Ended                             Ended                  
                   September                          Septemb…                  
             2026        30,    2025            2026       30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  income     $        14,161    $      5,074    $       10,065    $     -6,725  
  (loss)                                                                        
  Stock-…                                                                       
  compen…              7,823           8,699            28,200          30,344  
  expense                                                                       
  Deprec…                                                                       
  and                  3,627           2,944            10,514           8,456  
  amorti…                                                                       
  Net                                                                           
  intere…             -1,992          -1,654            -5,485          -4,658  
  income                                                                        
  Pre-oc…                                                                       
  lease                                                                         
  expense              1,604           1,933             6,349           6,180  
  and                                                                           
  tech                                                                          
  transf…                                                                       
  Adjust…                                                                       
  EBITDA     $        25,223    $     16,996    $       49,643    $     33,597  
  (Non-G…                                                                       
                                                                                
                                       7                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                              VERICEL CORPORATION                               
                                                                                
              RECONCILIATION OF FREE CASH FLOW (NON-GAAP MEASURE)               
                                                                                
                           (in thousands - unaudited)                           
                                                                                
                      Three                              Nine                   
                     Months                            Months                   
                      Ended                             Ended                   
                   Septemb…                          Septemb…                   
             2026       30,    2025            2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  provid…    $       17,723    $     22,082    $       50,297    $      36,896  
  by                                                                            
  operat…                                                                       
  activi…                                                                       
  Capital            -2,042          -2,630            -5,231          -24,975  
  expend…                                                                       
  Free                                                                          
  cash       $       15,681    $     19,452    $       45,066    $      11,921  
  flow                                                                          
  (Non-G…                                                                       
  Net                                                                           
  cash                                                                          
  used in    $       -2,708    $     -3,377    $       -9,729    $     -27,547  
  invest…                                                                       
  activi…                                                                       
  Net                                                                           
  cash                                                                          
  (used                                                                         
  in)        $       -6,880    $      1,166    $       -7,167    $       6,005  
  provid…                                                                       
  by                                                                            
  financ…                                                                       
  activi…                                                                       
                                                                                
                                       8                                        
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
                              VERICEL CORPORATION                               
                                                                                
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
                           (in thousands - unaudited)                           
                                                                                
  ASSETS                       September 30,             December 31,           
  Current assets:              2026                      2025                   
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents    $              133,493    $             100,092  
  Short-term investments                       36,775                   37,407  
  Accounts receivable (net                                                      
  of allowance                                                                  
  for doubtful accounts of                     81,798                   84,634  
  $23 and $13,                                                                  
  respectively)                                                                 
  Inventory                                    17,056                   17,560  
  Other current assets                         11,648                    7,744  
  Total current assets                        280,770                  247,437  
  Property and equipment,                     105,079                  108,397  
  net                                                                           
  Intangible assets, net                        5,156                    5,625  
  Right-of-use assets                          60,590                   64,774  
  Long-term investments                        65,336                   61,395  
  Other long-term assets                          179                      341  
  Total assets                 $              517,110    $             487,969  
  LIABILITIES AND                                                               
  SHAREHOLDERS’ EQUITY                                                          
  Current liabilities:                                                          
  Accounts payable             $               19,958    $              15,828  
  Accrued expenses                             20,391                   19,236  
  Current portion of                                                            
  operating lease                              14,254                   13,969  
  liabilities                                                                   
  Other current liabilities                       116                      116  
  Total current liabilities                    54,719                   49,149  
  Operating lease                              76,319                   82,284  
  liabilities                                                                   
  Other long-term                               1,900                    1,896  
  liabilities                                                                   
  Total liabilities                           132,938                  133,329  
  Total shareholders’                         384,172                  354,640  
  equity                                                                        
  Total liabilities and                                                         
  shareholders’                $              517,110    $             487,969  
  equity                                                                        
                                                                                
                                       9                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.